Peanut allergy and anaphylaxis

Current Opinion in Immunology

Volumn 22, Issue 6, 2010, Pages 783-788

  Finkelman, Fred D ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; FOOD ALLERGEN; HERBACEOUS AGENT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; PLACEBO; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ABSENCE OF SIDE EFFECTS; ANAPHYLAXIS; ASTHMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEMENT ACTIVATION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXPOSURE; FOOD INTAKE; HERBAL MEDICINE; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PEANUT ALLERGY; PREVALENCE; PROGNOSIS; PROVOCATION TEST; REVIEW;

ANAPHYLAXIS; ANIMALS; HUMANS; PEANUT HYPERSENSITIVITY;

EID: 78649878391     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.10.005     Document Type: Review

References (48)

1. Finkelman F.D., Hogan S.P., Hershey G.K., Rothenberg M.E., Wills-Karp M. Importance of cytokines in murine allergic airway disease and human asthma. J Immunol 2010, 184:1663-1674.
2. Clark S., Camargo C.A. Epidemiology of anaphylaxis. Immunol Allergy Clin North Am 2007, 27:145-163.
3. Matasar M.J., Neugut A.I. Epidemiology of anaphylaxis in the United States. Curr Allergy Asthma Rep 2003, 3:30-35.
4. Simons F.E. Anaphylaxis. J Allergy Clin Immunol 2010, 125:S161-181.
5. Sicherer S.H., Sampson H.A. Food allergy. J Allergy Clin Immunol 2010, 125:S116-S125.
6. Blanc F., Adel-Patient K., Drumare M.F., Paty E., Wal J.M., Bernard H. Capacity of purified peanut allergens to induce degranulation in a functional in vitro assay: Ara h 2 and Ara h 6 are the most efficient elicitors. Clin Exp Allergy 2009, 39:1277-1285.
7. Dodo H.W., Konan K.N., Chen F.C., Egnin M., Viquez O.M. Alleviating peanut allergy using genetic engineering: the silencing of the immunodominant allergen Ara h 2 leads to its significant reduction and a decrease in peanut allergenicity. Plant Biotechnol J 2008, 6:135-145.
8. Krause S., Reese G., Randow S., Zennaro D., Quaratino D., Palazzo P., Ciardiello M.A., Petersen A., Becker W.M., Mari A. Lipid transfer protein (Ara h 9) as a new peanut allergen relevant for a Mediterranean allergic population. J Allergy Clin Immunol 2009, 124:771-778.
9. Lauer I., Dueringer N., Pokoj S., Rehm S., Zoccatelli G., Reese G., Miguel-Moncin M.S., Cistero-Bahima A., Enrique E., Lidholm J., et al. The non-specific lipid transfer protein, Ara h 9, is an important allergen in peanut. Clin Exp Allergy 2009, 39:1427-1437.
10. van Wijk F., Nierkens S., Hassing I., Feijen M., Koppelman S.J., de Jong G.A., Pieters R., Knippels L.M. The effect of the food matrix on in vivo immune responses to purified peanut allergens. Toxicol Sci 2005, 86:333-341.
11. Sicherer S.H., Munoz-Furlong A., Godbold J.H., Sampson H.A. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol 2010, 125:1322-1326.
12. Ben-Shoshan M., Harrington D.W., Soller L., Fragapane J., Joseph L., St Pierre Y., Godefroy S.B., Elliot S.J., Clarke A.E. A population-based study on peanut, tree nut, fish, shellfish, and sesame allergy prevalence in Canada. J Allergy Clin Immunol 2010, 125:1327-1335.
13. Nicolaou N., Poorafshar M., Murray C., Simpson A., Winell H., Kerry G., Harlin A., Woodcock A., Ahlstedt S., Custovic A. Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. J Allergy Clin Immunol 2010, 125:191-197.
14. Simpson A.B., Yousef E., Hossain J. Association between peanut allergy and asthma morbidity. J Pediatr 2010, 156:777-781.
15. Liem J.J., Huq S., Kozyrskyj A.L., Becker A.B. Should younger siblings of peanut-allergic children be assessed by an allergist before being fed peanut?. Allergy Asthma Clin Immunol 2008, 4:144-149.
16. Du Toit G., Katz Y., Sasieni P., Mesher D., Maleki S.J., Fisher H.R., Fox A.T., Turcanu V., Amir T., Zadik-Mnuhin G., et al. Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. J Allergy Clin Immunol 2008, 122:984-991.
17. Fox A.T., Sasieni P., Du Toit G., Syed H., Lack G. Household peanut consumption as a risk factor for the development of peanut allergy. J Allergy Clin Immunol 2009, 123:417-423.
18. Thompson R.L., Miles L.M., Lunn J., Devereux G., Dearman R.J., Strid J., Buttriss J.L. Peanut sensitization and allergy: influence of early life exposure to peanuts. Br J Nutr 2010, 103:1278-1286.
19. Burks A.W. Early peanut consumption: postpone or promote?. J Allergy Clin Immunol 2009, 123:424-425.
20. Wang M., Takeda K., Shiraishi Y., Okamoto M., Dakhama A., Joetham A., Gelfand E.W. Peanut-induced intestinal allergy is mediated through a mast cell-IgE-Fce{open}RI-IL-13 pathway. J Allergy Clin Immunol 2010, [epub ahead of print].
21. Khodoun M., Strait R., Orekov T., Hogan S., Karasuyama H., Herbert D.R., Kohl J., Finkelman F.D. Peanuts can contribute to anaphylactic shock by activating complement. J Allergy Clin Immunol 2009, 123:342-351.
22. van der Linden P.W., Hack C.E., Kerckhaert J.A., Struyvenberg A., van der Zwan J.C. Preliminary report: complement activation in wasp-sting anaphylaxis. Lancet 1990, 336:904-906.
23. Sen M., Kopper R., Pons L., Abraham E.C., Burks A.W., Bannon G.A. Protein structure plays a critical role in peanut allergen stability and may determine immunodominant IgE-binding epitopes. J Immunol 2002, 169:882-887.
24. Maleki S.J., Kopper R.A., Shin D.S., Park C.W., Compadre C.M., Sampson H., Burks A.W., Bannon G.A. Structure of the major peanut allergen Ara h 1 may protect IgE-binding epitopes from degradation. J Immunol 2000, 164:5844-5849.
25. Kopper R.A., Odum N.J., Sen M., Helm R.M., Stanley J.S., Burks A.W. Peanut protein allergens: the effect of roasting on solubility and allergenicity. Int Arch Allergy Immunol 2005, 136:16-22.
26. Shreffler W.G., Castro R.R., Kucuk Z.Y., Charlop-Powers Z., Grishina G., Yoo S., Burks A.W., Sampson H.A. The major glycoprotein allergen from Arachis hypogaea, Ara h 1, is a ligand of dendritic cell-specific ICAM-grabbing nonintegrin and acts as a Th2 adjuvant in vitro. J Immunol 2006, 177:3677-3685.
27. Van den Berg C.W., Hazenberg M.A., Hofhuis F.M., Van Rooyen S.M., Van Dijk H. C3- and T-cell-dependent adjuvant activity of in vivo formed immune complexes. Immunology 1991, 73:264-270.
28. DeBrosse C.W., Collins M.H., Buckmeier Butz B.K., Allen C.L., King E.C., Assa'ad A.H., Abonia J.P., Putnam P.E., Rothenberg M.E., Franciosi J.P. Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982-1999. J Allergy Clin Immunol 2010, 126:112-119.
29. Erwin E.A., James H.R., Gutekunst H.M., Russo J.M., Kelleher K.J., Platts-Mills T.A. Serum IgE measurement and detection of food allergy in pediatric patients with eosinophilic esophagitis. Ann Allergy Asthma Immunol 2010, 104:496-502.
30. - Th2 responses. J Allergy Clin Immunol 2009, 124:1326-1332.
31. Stein M.L., Collins M.H., Villanueva J.M., Kushner J.P., Putnam P.E., Buckmeier B.K., Filipovich A.H., Assa'ad A.H., Rothenberg M.E. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006, 18:1312-1319.
32. Wainstein B.K., Studdert J., Ziegler M., Ziegler J.B. Prediction of anaphylaxis during peanut food challenge: usefulness of the peanut skin prick test (SPT) and specific IgE level. Pediatr Allergy Immunol 2010, 21:603-611.
33. Blumchen K., Ulbricht H., Staden U., Dobberstein K., Beschorner J., de Oliveira L.C., Shreffler W.G., Sampson H.A., Niggemann B., Wahn U., et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol 2010, 126:83-91.
34. Jones S.M., Pons L., Roberts J.L., Scurlock A.M., Perry T.T., Kulis M., Shreffler W.G., Steele P., Henry K.A., Adair M., et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009, 124:292-300.
35. Hofmann A.M., Scurlock A.M., Jones S.M., Palmer K.P., Lokhnygina Y., Steele P.H., Kamilaris J., Burks A.W. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol 2009, 124:286-291.
36. Boyle R.J., Tang M.L. Recurrent peanut allergy may not be prevented by continued peanut ingestion. Int Arch Allergy Immunol 2008, 147:260-262.
37. Thyagarajan A., Varshney P., Jones S.M., Sicherer S., Wood R., Vickery B.P., Sampson H., Burks A.W. Peanut oral immunotherapy is not ready for clinical use. J Allergy Clin Immunol 2010, 126:31-32.
38. Rafi A., Do L.T., Katz R., Sheinkopf L.E., Simons C.W., Klaustermeyer W. Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 2010, 31:76-83.
39. Leung D.Y., Sampson H.A., Yunginger J.W., Burks A.W., Schneider L.C., Wortel C.H., Davis F.M., Hyun J.D., Shanahan W.R. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003, 348:986-993.
40. Hamilton R.G., MacGlashan D.W., Saini S.S. IgE antibody-specific activity in human allergic disease. Immunol Res 2010, 47:273-284.
41. Cox L., Platts-Mills T.A., Finegold I., Schwartz L.B., Simons F.E., Wallace D.V. Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007, 120:1373-1377. American Academy of Allergy, Asthma & Immunology/American College of Allergy.
42. + T cells. J Allergy Clin Immunol 2009, 123:443-451.
43. Wang J., Patil S.P., Yang N., Ko J., Lee J., Noone S., Sampson H.A., Li X.M. Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol 2010, 105:75-84.
44. Brandt E.B., Strait R.T., Hershko D., Wang Q., Muntel E.E., Scribner T.A., Zimmermann N., Finkelman F.D., Rothenberg M.E. Mast cells are required for experimental oral allergen-induced diarrhea. J Clin Invest 2003, 112:1666-1677.
45. Arias K., Baig M., Colangelo M., Chu D., Walker T., Goncharova S., Coyle A., Vadas P., Waserman S., Jordana M. Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. J Allergy Clin Immunol 2009, 124:307-314.
46. Strait R.T., Morris S.C., Yang M., Qu X.W., Finkelman F.D. Pathways of anaphylaxis in the mouse. J Allergy Clin Immunol 2002, 109:658-668.
47. Vadas P., Gold M., Perelman B., Liss G.M., Lack G., Blyth T., Simons F.E., Simons K.J., Cass D., Yeung J. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008, 358:28-35.
48. Gomez F.P., Rodriguez-Roisin R. Platelet-activating factor antagonists: current status in asthma. BioDrugs 2000, 14:21-30.